Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of NB-4746 compared with placebo in adults with amyotrophic lateral sclerosis ALS. This trial aims to understand the safety, side effects, how NB-4746 moves through the body, and changes in a blood marker called neurofilament light NfL, which indicates nerve cell damage. The study is divided into two parts and includes an optional open-label extension. In Part A, participants are randomly assigned to receive either a low dose of NB-4746, a high dose of NB-4746, or placebo capsules taken twice daily for about one month. In Part B, participants are again randomized to receive NB-4746 at a dose determined based on Part A results or placebo capsules twice daily for about twelve weeks. After completing Part A or B, participants may opt to continue treatment in an open-label extension lasting up to one year. Participants will be monitored throughout the trial with regular health checks focusing on ALS symptoms and overall wellbeing. Researchers will track adverse events, measure blood levels of NB-4746, and assess changes in neurofilament light to evaluate nerve damage. Safety and tolerability will be evaluated from enrollment through the treatment periods, with ongoing monitoring during the extension phase.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and potential to slow disease progression of votoplam in adults with early symptomatic Huntingtons disease. This phase 3 study compares votoplam to a placebo in a double-blind, randomized design sponsored by Novartis Pharmaceuticals. The study focuses on measuring changes in clinical scores that reflect disease status and progression over time. Participants will be randomly assigned in a 32 ratio to receive either votoplam or a placebo orally. The study includes three periods a screening phase lasting up to 42 days to determine eligibility a double-blind treatment phase with a variable duration of up to 36 months, where not all participants will complete the full duration and a safety follow-up period consisting of one visit or phone call approximately 30 days after the end of the study. The treatment period ends when at least 50% of participants reach month 36. During participation, individuals will undergo various assessments including clinical rating scales such as the composite Unified Huntingtons Disease Rating Scale cUHDRS, functional capacity scores, motor scores, cognitive tests, and blood tests to measure mutant huntingtin protein levels and neurofilament light chain. Safety will be monitored throughout for adverse events. The study aims to gather detailed information on both the effects and safety of votoplam over the treatment period and shortly after treatment ends.
Actively Recruiting
This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.
Actively Recruiting
Researchers are evaluating Usnoflast in adults with Amyotrophic Lateral Sclerosis ALS to study its effects on disease progression, safety, and how the drug works in the body. This phase 2b trial is randomized, double-blind, placebo-controlled, and parallel-group across multiple centers, aiming to assess Usnoflasts efficacy and safety over 36 weeks, followed by an open-label extension. The study addresses the urgent need for new treatments for ALS, a progressive neuromuscular disease. Participants receive either 50 mg or 75 mg doses of Usnoflast or matching placebo capsules twice daily under fasting conditions for 36 weeks. After this period, eligible participants from all groups can join a 16-week open-label extension where everyone receives 75 mg Usnoflast twice daily. This extension helps confirm the long-term safety and effectiveness of Usnoflast. During the study, participants will be regularly assessed for motor function using the ALS Functional Rating Scale-Revised, survival rates, lung function, and biomarkers in blood and cerebrospinal fluid. Researchers will monitor drug levels in plasma and cerebrospinal fluid at specific times after dosing. Safety will be carefully tracked, including any adverse events. The total participation can last up to 52 weeks, including the treatment and extension phases.